Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
NICE currently recommends Biogen’s Spinraza (nusinersen) for certain patients with pre-symptomatic SMA and SMA types 1, 2 or 3 as part of a managed access agreement.
Latest news
-
ICER extends evaluation of Biogen’s aducanumab after FDA delay
The FDA considered the additional information a ‘major amendment’ to Biogen’s application, hence the need for the additional time for review. ... It is unclear what additional data Biogen submitted to the FDA after the agency’s request for
-
Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes
Another amyloid-targeting treatment, Biogen’s aducanumab, is currently being reviewed by the US Food and Drug Administration (FDA).
-
Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma
Biogen has treated the first patient in a phase 4 study evaluating its spinal muscular atrophy (SMA) treatment Spinraza in infants and children who have ‘unmet clinical needs’ after previously receiving ... Despite launching as a one-time treatment
-
New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU
Biogen’s MS franchise also includes its oral therapy Tecfidera (dimethyl fumarate), although the cmpany has been facing patent challenges to the drug recently. ... Aside from MS, Biogen has high hopes for its potential Alzheimer’s disease therapy
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
One of the most promising potential treatments of late to come through the development pipeline for Alzheimer’s is Biogen’s aducanumab, which is currently under review with the US Food
More from news
Approximately 134 fully matching, plus 314 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
More from intelligence
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Attigo (part of the Mednet Group)
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
Strategic planning - to ensure sustained engagement and ongoing success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, HRA Pharma, Janssen, Leo Pharma, Mylan,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
Account handling roles, All Levels
-
Competitive Salary and Dependent on Experience
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Sinopharm’s COVID-19 vaccine scores approval in China
- Categories - Communiqué Awards
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- The role of women in science and technology
- Syneos Health Communications announces senior hires to Europe-based team
- IWD2021: #ChooseToChallenge Interview with Dennis O’Brien, Lucid Group CEO
- Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
- Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
- EMA recommends use of Lilly’s COVID-19 antibody cocktail
- Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise
- ZENO GROUP HIRES AVRIL LEE AS HEAD OF HEALTHCARE, U.K. AND EUROPE
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Choose to challenge for women’s health on this International Women's Day
- Today, you could be taking the time to reflect on the inspirational achievements of many women across the world. Or maybe you’re a woman yourself, and you want to take...
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Quick links
Infographics
